Alnylam Pharmaceuticals Ownership | Who Owns Alnylam Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Alnylam Pharmaceuticals Ownership Summary


Alnylam Pharmaceuticals is owned by 102.93% institutional investors, 3.80% insiders. Capital world investors is the largest institutional shareholder, holding 12.96% of ALNY shares. Capital Group Growth Fnd of Amer Comp is the top mutual fund, with 7.81% of its assets in Alnylam Pharmaceuticals shares.

ALNY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAlnylam Pharmaceuticals102.93%3.80%-6.73%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Capital world investors16.81M12.96%$5.48B
Fmr13.49M10.49%$3.17B
Vanguard group12.73M9.90%$3.00B
Blackrock funding, inc. /de9.98M7.70%$3.25B
Blackrock9.55M7.57%$2.32B
Capital research global investors7.19M5.55%$2.35B
Regeneron pharmaceuticals4.44M3.43%$1.45B
T. rowe price investment management4.28M3.30%$1.40B
Wellington management group llp4.20M3.26%$987.51M
Baillie gifford4.04M3.14%$950.71M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals4.44M97.59%$1.45B
Palo alto investors lp75.53K5.24%$24.63M
Bellevue group676.37K4.86%$220.56M
Eagle health investments lp76.26K4.40%$17.94M
Ikarian capital56.59K3.54%$18.45M
Parkman healthcare partners92.34K3.46%$30.11M
Orbis allan gray2.12M3.36%$691.77M
Orbimed advisors341.90K2.79%$111.49M
Rosenblum silverman sutton s f inc /ca34.39K2.72%$11.21M
Casdin capital81.50K2.42%$26.58M

Top Buyers

HolderShares% AssetsChange
Norges bank2.46M0.08%2.46M
Holocene advisors, lp596.82K0.47%596.82K
Blackrock9.55M0.05%522.66K
Orbis allan gray2.12M3.36%486.49K
Blackrock funding, inc. /de9.98M0.06%420.78K

Top Sellers

HolderShares% AssetsChange
Capital investors---1.42M
Fmr13.49M0.19%-1.19M
Baillie gifford4.04M0.73%-846.74K
Wellington management group llp4.20M0.18%-756.72K
Logos global management lp---500.00K

New Positions

HolderShares% AssetsChangeValue
Norges bank2.46M0.08%2.46M$577.94M
Holocene advisors, lp596.82K0.47%596.82K$194.62M
Bank of america corp /de/83.50K0.00%83.50K$20.29M
Kynam capital management, lp43.00K0.81%43.00K$10.45M
Fjarde ap-fonden (the fourth swedish national pensionfund)28.41K0.08%28.41K$6.91M

Sold Out

HolderChange
Bear mountain capital-1.00
Financial gravity asset management-1.00
Johnson financial group-1.00
Salem investment counselors-1.00
Halbert hargrove global advisors-1.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20256852.09%133,478,5513.70%1021.04%3541.14%22010.00%
Mar 31, 202528-95.52%1,770,848-98.63%10.01%11-96.63%10-94.71%
Dec 31, 2024603-0.33%129,230,8605.02%1001.10%315-2.78%1836.40%
Sep 30, 20245994.17%123,006,4572.58%951.07%32010.73%1704.94%
Jun 30, 20245713.25%119,905,1276.57%951.19%2864.38%1623.18%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Capital Group Growth Fnd of Amer Comp10.18M7.81%-
American Funds Growth Fund of Amer A10.18M7.81%-
Vanguard US Total Market Shares ETF4.07M3.15%54.28K
Vanguard Total Stock Mkt Idx Inv4.10M3.13%-95.47K
VA CollegeAmerica Amcap 529A3.73M2.89%658.62K
Capital Group New Perspective Comp2.93M2.25%-
American Funds New Perspective A2.93M2.25%-
Vanguard Mid Cap Index Institutional2.91M2.22%31.33K
Capital Group AMCAP Composite2.40M1.84%-
American Funds AMCAP A2.40M1.84%-

Recent Insider Transactions


DateNameRoleActivityValue
Aug 18, 2025Garg Pushkal EVP Chief R&DSell$46.55K
Aug 18, 2025Garg Pushkal EVP Chief R&DSell$17.47K
Aug 18, 2025Garg Pushkal EVP Chief R&DSell$40.49K
Aug 18, 2025Garg Pushkal EVP Chief R&DSell$17.59K
Aug 18, 2025Garg Pushkal EVP Chief R&DSell$149.02K

Insider Transactions Trends


DateBuySell
2025 Q3-58
2025 Q2-17
2025 Q1-152
2024 Q4-36
2024 Q3-16

ALNY Ownership FAQ


Who Owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals shareholders are primarily institutional investors at 102.93%, followed by 3.80% insiders and -6.73% retail investors. The average institutional ownership in Alnylam Pharmaceuticals's industry, Biotech Stocks , is 304.14%, which Alnylam Pharmaceuticals falls below.

Who owns the most shares of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s largest shareholders are Capital world investors (16.81M shares, 12.96%), Fmr (13.49M shares, 10.49%), and Vanguard group (12.73M shares, 9.90%). Together, they hold 33.35% of Alnylam Pharmaceuticals’s total shares outstanding.

Does Blackrock own Alnylam Pharmaceuticals?

Yes, BlackRock owns 7.57% of Alnylam Pharmaceuticals, totaling 9.55M shares as of Jun 2024. This represents 0.05% of BlackRock's total assets, with a market value of 2.32B$. In the last quarter, BlackRock increased its holdings by 522.66K shares, a 5.79% change.

Who is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Alnylam Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 97.59% of its assets in 4.44M Alnylam Pharmaceuticals shares, valued at 1.45B$.

Who is the top mutual fund holder of Alnylam Pharmaceuticals shares?

Capital Group Growth Fnd of Amer Comp is the top mutual fund holder of Alnylam Pharmaceuticals shares, with 7.81% of its total shares outstanding invested in 10.18M Alnylam Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools